Compensated liver cirrhosis:Natural course and disease-modifying strategies

作     者：Ramesh Kumar Sudhir Kumar Sabbu Surya Prakash 

作者机构：Department of GastroenterologyAll India Institute of Medical SciencesPatna 801507India 

出 版 物：《World Journal of Methodology》 (世界方法学杂志)

年 卷 期：2023年第13卷第4期

页      面：179-193页

学科分类：083002[工学-环境工程] 0830[工学-环境科学与工程（可授工学、理学、农学学位）] 08[工学] 

主　　题：Compensated cirrhosis Compensated advanced chronic liver disease Clinical decompensation Cirrhosis reversal Disease-modifying agents Acute-on-chronic liver failure 

摘      要：Compensated liver cirrhosis(CLC)is defined as cirrhosis with one or more decompensating events,such as ascites,variceal haemorrhage,or hepatic *** with CLC are largely asymptomatic with preserved hepatic *** transition from CLC to decompensated cirrhosis occurs as a result of a complex interaction between multiple predisposing and precipitating *** first decompensation event in CLC patients is considered a significant turning point in the progression of cirrhosis,as it signals a drastic decline in median survival rates from 10-12 years to only 1-2 ***,early cirrhosis has the potential to regress as liver fibrosis is a dynamic *** the advent of effective non-invasive tools for detecting hepatic fibrosis,more and more patients with CLC are currently being *** offers clinicians a unique opportunity to properly manage such patients in order to achieve cirrhosis regression or,at the very least,prevent its *** are numerous emerging approaches for preventing or delaying decompensation in CLC patients.A growing body of evidence indicates that treating the underlying cause can lead to cirrhosis regression,and the use of non-selective beta-blockers can prevent decompensation by lowering portal ***,address-ing various cofactors(such as obesity,diabetes,dyslipidaemia,and alcoholism)and precipitating factors(such as infection,viral hepatitis,and hepatotoxic drugs)that have a detrimental impact on the natural course of cirrhosis may benefit patients with ***,high-quality data must be generated through well-designed and adequately powered randomised clinical trials to validate these diseasemodifying techniques for CLC *** article discussed the natural history of CLC,risk factors for its progression,and therapeutic approaches that could alter the trajectory of CLC evolution and improve outcomes.